GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abbisko Cayman Ltd (HKSE:02256) » Definitions » Net Margin %

Abbisko Cayman (HKSE:02256) Net Margin % : 41.59% (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Abbisko Cayman Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Abbisko Cayman's Net Income for the six months ended in Jun. 2024 was HK$222.6 Mil. Abbisko Cayman's Revenue for the six months ended in Jun. 2024 was HK$535.3 Mil. Therefore, Abbisko Cayman's net margin for the quarter that ended in Jun. 2024 was 41.59%.

The historical rank and industry rank for Abbisko Cayman's Net Margin % or its related term are showing as below:

HKSE:02256' s Net Margin % Range Over the Past 10 Years
Min: -7979.97   Med: -5122.18   Max: -3.98
Current: -3.98


HKSE:02256's Net Margin % is ranked better than
73.25% of 1013 companies
in the Biotechnology industry
Industry Median: -140.3 vs HKSE:02256: -3.98

Abbisko Cayman Net Margin % Historical Data

The historical data trend for Abbisko Cayman's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abbisko Cayman Net Margin % Chart

Abbisko Cayman Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
- - -7,979.97 - -2,264.38

Abbisko Cayman Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Margin % Get a 7-Day Free Trial Premium Member Only - - -1,094.42 - 41.59

Competitive Comparison of Abbisko Cayman's Net Margin %

For the Biotechnology subindustry, Abbisko Cayman's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abbisko Cayman's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abbisko Cayman's Net Margin % distribution charts can be found below:

* The bar in red indicates where Abbisko Cayman's Net Margin % falls into.



Abbisko Cayman Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Abbisko Cayman's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-472.056/20.847
=-2,264.38 %

Abbisko Cayman's Net Margin for the quarter that ended in Jun. 2024 is calculated as

Net Margin=Net Income (Q: Jun. 2024 )/Revenue (Q: Jun. 2024 )
=222.62/535.336
=41.59 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Abbisko Cayman  (HKSE:02256) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Abbisko Cayman Net Margin % Related Terms

Thank you for viewing the detailed overview of Abbisko Cayman's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Abbisko Cayman Business Description

Traded in Other Exchanges
Address
Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The company has only one business segment which is the development of innovative medicines.
Executives
Lav Asset Management (hong Kong) Limited 2102 Investment manager
Shi Yi 2201 Interest of corporation controlled by you
Xu Yao-chang 2101 Beneficial owner
Yu Hongping 2501 Other
Chen Zhui 2501 Other
Futu Trustee Limited 2301 Trustee
Temasek Holdings (private) Limited 2201 Interest of corporation controlled by you
Yu Hongping 2501 Other
Morgan Stanley 2201 Interest of corporation controlled by you
Temasek Life Sciences Private Limited
Trident Trust Company (hk) Limited 2301 Trustee
Computershare Hong Kong Trustees Limited 2301 Trustee
Morgan Stanley Investments (uk) 2201 Interest of corporation controlled by you
Morgan Stanley International Limited 2201 Interest of corporation controlled by you
Morgan Stanley International Holdings Inc. 2201 Interest of corporation controlled by you

Abbisko Cayman Headlines

No Headlines